Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug

Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis

(2010) Hui-fang Zhou et al.   Nanomedicine

αvβ3-Targeted nanotherapy suppresses inflammatory arthritis in mice

(2009) Hui-fang Zhou et al.   FASEB JOURNAL

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

(2009) Neelesh R. Soman et al.   JOURNAL OF CLINICAL INVESTIGATION

Carbamate Analogues of Fumagillin as Potent, Targeted Inhibitors of Methionine Aminopeptidase-2

(2009) Christopher C. Arico-Muendel et al.   JOURNAL OF MEDICINAL CHEMISTRY

Involution of Collagen-Induced Arthritis with an Angiogenesis Inhibitor, PPI-2458

(2009) E. Brahn et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Exploiting lipid raft transport with membrane targeted nanoparticles: A strategy for cytosolic drug delivery

(2008) Kathryn C. Partlow et al.   BIOMATERIALS

Phospholipase A2 Biochemistry

(2008) John E. Burke et al.   CARDIOVASCULAR DRUGS AND THERAPY

Minute dosages of ανβ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits

(2008) Patrick M. Winter et al.   FASEB JOURNAL

Three-dimensional MR mapping of angiogenesis with α5β1(ανβ3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model

(2008) Anne H. Schmieder et al.   FASEB JOURNAL

Antiangiogenic Synergism of Integrin-Targeted Fumagillin Nanoparticles and Atorvastatin in Atherosclerosis

(2008) Patrick M. Winter et al.   JACC-Cardiovascular Imaging

The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration

(2007) Arik Dahan et al.   JOURNAL OF CONTROLLED RELEASE